Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: A study of the EORTC early clinical studies group (ECSG)
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Aamdal, S. | en |
dc.contributor.author | Awada, Ahmad | en |
dc.contributor.author | Calvert, H. | en |
dc.contributor.author | Fumoleau, P. | en |
dc.contributor.author | Sorio, R. | en |
dc.contributor.author | Punt, C. | en |
dc.contributor.author | Verweij, J. | en |
dc.contributor.author | Oosterom, A. T. Van | en |
dc.contributor.author | Morant, R. | en |
dc.contributor.author | Wanders, J. | en |
dc.contributor.author | Hanauske, A. R. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Aamdal, S. | en |
dc.creator | Awada, Ahmad | en |
dc.creator | Calvert, H. | en |
dc.creator | Fumoleau, P. | en |
dc.creator | Sorio, R. | en |
dc.creator | Punt, C. | en |
dc.creator | Verweij, J. | en |
dc.creator | Oosterom, A. T. Van | en |
dc.creator | Morant, R. | en |
dc.creator | Wanders, J. | en |
dc.creator | Hanauske, A. R. | en |
dc.date.accessioned | 2018-06-22T09:54:18Z | |
dc.date.available | 2018-06-22T09:54:18Z | |
dc.date.issued | 2000 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42294 | |
dc.description.abstract | Purpose: In a phase II trial, the activity of carzelesin, a cyclopropylpyrroloindole prodrug analog, was assessed. Patients and methods: Carzelesin was used as second- or third-line chemotherapy in patients with breast, ovarian, head and neck cancer and non-Hodgkin's lymphoma, and as first-line chemotherapy in patients with colorectal and gastric cancer and melanoma. The drug was given as a bolus infusion at a 4-weekly dose of 150 μg/m2. A total of 140 patients were entered and a total of 285 courses were administered. Results: In general, the compound was well tolerated. Myelotoxicity was the most common toxicity. Grade 3 and 4 leukopenia was observed in 18.6% of the courses, neutropenia in 20.3%, thrombocytopenia in 16.2% and anemia in 8.7%. Double nadirs were seen in a total of 41 courses for neutrophils, in 40 for leukocytes and in 3 for platelets Non-hematological toxicity was very mild. Only one partial response in a patient with melanoma was seen. Conclusions: At this dose and schedule carzelesin did not yield activity in the types of tumors studied. | en |
dc.language.iso | eng | en |
dc.source | Cancer chemotherapy and pharmacology | en |
dc.subject | Article | en |
dc.subject | Antineoplastic agents | en |
dc.subject | Human | en |
dc.subject | Neoplasms | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Breast cancer | en |
dc.subject | Breast neoplasms | en |
dc.subject | Female | en |
dc.subject | Major clinical study | en |
dc.subject | Middle aged | en |
dc.subject | Advanced cancer | en |
dc.subject | Neoplasm staging | en |
dc.subject | Ovarian neoplasms | en |
dc.subject | Ovary cancer | en |
dc.subject | Priority journal | en |
dc.subject | Clinical trial | en |
dc.subject | Neutropenia | en |
dc.subject | Phase 2 clinical trial | en |
dc.subject | Thrombocytopenia | en |
dc.subject | Infusions | en |
dc.subject | Intravenous | en |
dc.subject | Fever | en |
dc.subject | Nonhodgkin lymphoma | en |
dc.subject | Colorectal cancer | en |
dc.subject | Melanoma | en |
dc.subject | Male | en |
dc.subject | Lymphoma | en |
dc.subject | Solid tumors | en |
dc.subject | Stomach neoplasms | en |
dc.subject | Colorectal neoplasms | en |
dc.subject | Stomach cancer | en |
dc.subject | Blood toxicity | en |
dc.subject | Bone marrow toxicity | en |
dc.subject | Indoles | en |
dc.subject | Head and neck cancer | en |
dc.subject | Head and neck neoplasms | en |
dc.subject | Non-hodgkin | en |
dc.subject | Bone marrow depression | en |
dc.subject | Benzofurans | en |
dc.subject | Carzelesin | en |
dc.subject | Covalent bond | en |
dc.subject | Prodrugs | en |
dc.subject | Toxicity | en |
dc.title | Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: A study of the EORTC early clinical studies group (ECSG) | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1007/s002800000134 | |
dc.description.volume | 46 | |
dc.description.issue | 2 | |
dc.description.startingpage | 167 | |
dc.description.endingpage | 171 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |